These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 16935474)

  • 21. Non-viral mediated gene transfer of porphobilinogen deaminase into mammalian cells.
    Johansson A; Möller C; Gellerfors P; Harper P
    Scand J Clin Lab Invest; 2002; 62(2):105-13. PubMed ID: 12004925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria.
    D'Avola D; López-Franco E; Sangro B; Pañeda A; Grossios N; Gil-Farina I; Benito A; Twisk J; Paz M; Ruiz J; Schmidt M; Petry H; Harper P; de Salamanca RE; Fontanellas A; Prieto J; González-Aseguinolaza G
    J Hepatol; 2016 Oct; 65(4):776-783. PubMed ID: 27212246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of a prevalent nonsense mutation (W283X) and two novel mutations in the porphobilinogen deaminase gene of Swiss patients with acute intermittent porphyria.
    Schneider-Yin X; Bogard C; Rüfenacht UB; Puy H; Nordmann Y; Minder EI; Deybach J
    Hum Hered; 2000; 50(4):247-50. PubMed ID: 10782018
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel mutation in the porphobilinogen deaminase gene in an extended Chinese family with acute intermittent porphyria.
    Yang J; Wang H; Yin K; Hua B; Zhu T; Zhao Y; Guo S; Yu X; Wu W; Zhou Z
    Gene; 2015 Jul; 565(2):288-90. PubMed ID: 25870942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Haem precursors and porphobilinogen deaminase in erythrocytes and lymphocytes of patients with acute intermittent porphyria.
    Gross U; Jacob K; Frank M; Doss MO
    Cell Mol Biol (Noisy-le-grand); 1997 Feb; 43(1):29-35. PubMed ID: 9074786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel mutation in a family with non-erythroid variant form of acute intermittent porphyria.
    Yu S; Poulos V; Stewart P
    J Hum Genet; 2000; 45(6):367-9. PubMed ID: 11185747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Porphobilinogen deaminase gene structure and molecular defects.
    Deybach JC; Puy H
    J Bioenerg Biomembr; 1995 Apr; 27(2):197-205. PubMed ID: 7592566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute intermittent porphyria--impact of mutations found in the hydroxymethylbilane synthase gene on biochemical and enzymatic protein properties.
    Ulbrichova D; Hrdinka M; Saudek V; Martasek P
    FEBS J; 2009 Apr; 276(7):2106-15. PubMed ID: 19292878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disease pharmacokinetic-pharmacodynamic modelling in acute intermittent porphyria to support the development of mRNA-based therapies.
    Parra-Guillen ZP; Fontanellas A; Jiang L; Jericó D; Martini P; Vera-Yunca D; Hard M; Guey LT; Troconiz IF
    Br J Pharmacol; 2020 Jul; 177(14):3168-3182. PubMed ID: 32133631
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CRIM-positive mutations of acute intermittent porphyria in Finland.
    Kauppinen R; Peltonen L; Pihlaja H; Mustajoki P
    Hum Mutat; 1992; 1(5):392-6. PubMed ID: 1301948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular study of the hydroxymethylbilane synthase gene (HMBS) among Polish patients with acute intermittent porphyria.
    Gregor A; Schneider-Yin X; Szlendak U; Wettstein A; Lipniacka A; Rüfenacht UB; Minder EI
    Hum Mutat; 2002 Mar; 19(3):310. PubMed ID: 11857754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification and characterization of two novel mutations that produce acute intermittent porphyria: A 3-base deletion (841-843delGGA) and a missense mutation (T35M).
    De Siervi A; Weiss Cádiz DE; Parera VE; del C Batlle AM; Rossetti MV
    Hum Mutat; 2000 Oct; 16(4):373. PubMed ID: 11013452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An odd case of heteroallelic acute intermittent porphyria in the Argentinean population.
    Piñeiro Pauwels MB; Gerez EN; Martinez MC; Melito VA; Parera VE; Batlle A; Rossetti MV
    Cell Mol Biol (Noisy-le-grand); 2013 Mar; 59 Suppl():OL1855-60. PubMed ID: 23522335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and liver transduction efficacy of rAAV5-cohPBGD in nonhuman primates: a potential therapy for acute intermittent porphyria.
    Pañeda A; Lopez-Franco E; Kaeppel C; Unzu C; Gil-Royo AG; D'Avola D; Beattie SG; Olagüe C; Ferrero R; Sampedro A; Mauleon I; Hermening S; Salmon F; Benito A; Gavira JJ; Cornet ME; del Mar Municio M; von Kalle C; Petry H; Prieto J; Schmidt M; Fontanellas A; González-Aseguinolaza G
    Hum Gene Ther; 2013 Dec; 24(12):1007-17. PubMed ID: 24070415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ALAD Inhibition by Porphobilinogen Rationalizes the Accumulation of δ-Aminolevulinate in Acute Porphyrias.
    San Juan I; Pereira-Ortuzar T; Cendoya X; Laín A; To-Figueras J; Mateos B; Planes FJ; Bernardo-Seisdedos G; Mato JM; Millet O
    Biochemistry; 2022 Nov; 61(21):2409-2416. PubMed ID: 36241173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequency of low erythrocyte porphobilinogen deaminase activity in Finland.
    Mustajoki P; Kauppinen R; Lannfelt L; Lilius L; Koistinen J
    J Intern Med; 1992 Apr; 231(4):389-95. PubMed ID: 1588264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding Carbohydrate Metabolism and Insulin Resistance in Acute Intermittent Porphyria.
    Solares I; Jericó D; Córdoba KM; Morales-Conejo M; Ena J; Enríquez de Salamanca R; Fontanellas A
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 5-Aminolevulinate dehydratase porphyria: Update on hepatic 5-aminolevulinic acid synthase induction and long-term response to hemin.
    Lahiji AP; Anderson KE; Chan A; Simon A; Desnick RJ; Ramanujam VMS
    Mol Genet Metab; 2020 Dec; 131(4):418-423. PubMed ID: 33199206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure of human porphobilinogen deaminase at 2.8 A: the molecular basis of acute intermittent porphyria.
    Gill R; Kolstoe SE; Mohammed F; Al D-Bass A; Mosely JE; Sarwar M; Cooper JB; Wood SP; Shoolingin-Jordan PM
    Biochem J; 2009 Apr; 420(1):17-25. PubMed ID: 19207107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of eleven mutations causing acute intermittent porphyria using denaturing gradient gel electrophoresis.
    Gu XF; de Rooij F; Voortman G; Te Velde K; Deybach JC; Nordmann Y; Grandchamp B
    Hum Genet; 1994 Jan; 93(1):47-52. PubMed ID: 8270254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.